Literature DB >> 26194765

Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells.

Adam Linley1, Sergey Krysov2, Maurilio Ponzoni3, Peter W Johnson1, Graham Packham1, Freda K Stevenson1.   

Abstract

The vast majority of cases of follicular lymphoma (FL), but not normal B cells, acquire N-glycosylation sites in the immunoglobulin variable regions during somatic hypermutation. Glycans added to sites are unusual in terminating at high mannoses. We showed previously that the C-type lectins, dendritic cell-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN) and mannose receptor, bound to FL surface immunoglobulin (sIg), generating an intracellular Ca(2+) flux. We have now mapped further intracellular pathways activated by DC-SIGN in a range of primary FL cells with detection of phosphorylated ERK1/2, AKT, and PLCγ2. The SYK inhibitor (tamatinib) or the BTK inhibitor (ibrutinib) each blocked phosphorylation. Activation by DC-SIGN occurred in both IgM(+) and IgG(+) cases and led to upregulation of MYC expression, with detection in vivo observed in lymph nodes. Unlike cells of chronic lymphocytic leukemia, FL cells expressed relatively high levels of sIg, unchanged by long-term incubation in vitro, indicating no antigen-mediated downregulation in vivo. In contrast, expression of CXCR4 increased in vitro. Engagement of sIg in FL cells or normal B cells by anti-Ig led to endocytosis in vitro as expected, but DC-SIGN, even when cross-linked, did not lead to significant endocytosis of sIg. These findings indicate that lectin binding generates signals via sIg but does not mediate endocytosis, potentially maintaining a supportive antigen-independent signal in vivo. Location of DC-SIGN in FL tissue revealed high levels in sinusoidlike structures and in some colocalized mononuclear cells, suggesting a role for lectin-expressing cells at this site.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26194765     DOI: 10.1182/blood-2015-04-640805

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies.

Authors:  Huining Su; Mimi Wang; Xingchen Pang; Feng Guan; Xiang Li; Ying Cheng
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

2.  DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma.

Authors:  Rada Amin; Frédéric Mourcin; Fabrice Uhel; Céline Pangault; Philippe Ruminy; Loic Dupré; Marion Guirriec; Tony Marchand; Thierry Fest; Thierry Lamy; Karin Tarte
Journal:  Blood       Date:  2015-08-13       Impact factor: 22.113

Review 3.  Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?

Authors:  John C Allen; Fatima Talab; Joseph R Slupsky
Journal:  Int J Hematol Oncol       Date:  2016-05-26

Review 4.  Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach.

Authors:  Kirsten M Boughan; Paolo F Caimi
Journal:  Curr Oncol Rep       Date:  2019-05-23       Impact factor: 5.075

Review 5.  From genetics to the clinic: a translational perspective on follicular lymphoma.

Authors:  Sarah Huet; Pierre Sujobert; Gilles Salles
Journal:  Nat Rev Cancer       Date:  2018-02-09       Impact factor: 60.716

6.  Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing.

Authors:  A Zamò; J Pischimarov; M Schlesner; P Rosenstiel; R Bomben; H Horn; T Grieb; T Nedeva; C López; A Haake; J Richter; L Trümper; C Lawerenz; W Klapper; P Möller; M Hummel; D Lenze; M Szczepanowski; L Flossbach; M Schreder; V Gattei; G Ott; R Siebert; A Rosenwald; E Leich
Journal:  Leukemia       Date:  2017-08-21       Impact factor: 11.528

7.  Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region.

Authors:  Fleur S van de Bovenkamp; Ninotska I L Derksen; Pleuni Ooijevaar-de Heer; Karin A van Schie; Simone Kruithof; Magdalena A Berkowska; C Ellen van der Schoot; Hanna IJspeert; Mirjam van der Burg; Ann Gils; Lise Hafkenscheid; René E M Toes; Yoann Rombouts; Rosina Plomp; Manfred Wuhrer; S Marieke van Ham; Gestur Vidarsson; Theo Rispens
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-05       Impact factor: 11.205

8.  IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution.

Authors:  Mariette Odabashian; Emanuela Carlotti; Shamzah Araf; Jessica Okosun; Filomena Spada; John G Gribben; Francesco Forconi; Freda K Stevenson; Mariarita Calaminici; Sergey Krysov
Journal:  Blood       Date:  2020-03-12       Impact factor: 22.113

Review 9.  Follicular lymphoma: are we ready for a risk-adapted approach?

Authors:  Brad S Kahl
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

10.  Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.

Authors:  Elizabeth A Lemm; Beatriz Valle-Argos; Lindsay D Smith; Johanna Richter; Yohannes Gebreselassie; Matthew J Carter; Jana Karolova; Michael Svaton; Karel Helman; Nicola J Weston-Bell; Laura Karydis; Chris T Williamson; Georg Lenz; Jeremy Pettigrew; Curtis Harwig; Freda K Stevenson; Mark Cragg; Francesco Forconi; Andrew J Steele; Jennifer Cross; Lloyd Mackenzie; Pavel Klener; Graham Packham
Journal:  Clin Cancer Res       Date:  2019-12-12       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.